ACB - Catalyst Biosciences Results Positive And Other News: The Good Bad And Ugly Of Biopharma
Catalyst Biosciences Receives a Boost with Positive Study Readout
Catalyst Biosciences (CBIO) reported that it has obtained positive results from a Phase 2b clinical trial of its Factor IX therapy. This open label study involved six patients suffering from severe hemophilia B. The daily subcutaneous administration of Dalcinonacog Alfa (DalcA) for 28 days showed more than 12 percent FIX levels with steady state levels up to 27 percent after 14 days. No bleeds were experienced during that time period.
The trial demonstrated effective prophylaxis as well as the potential for lower or less